For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

Glenmark Pharma Shares Jump 40% On Launch Of New COVID-19 Drug

|

Shares of Glenmark Pharmaceuticals rose as much as 40 percent, its biggest-ever intraday gain, to its 52-week high of Rs 573.05 on Monday on launching its antiviral drug Favipiravir for the treatment of COVID-19 patients with mild to moderate symptoms.

Glenmark Pharma Shares Jump 40% On Launch Of New COVID-19 Drug
 

The Mumbai-based pharma company, after receiving approval from the Drugs Controller General of India (DCGI), launched Favipiravir under the brand name FabiFlu. Sold at Rs 103 per tablet, it is the first oral favipiravir-approved medication in India that received permission to conduct phase-3 for the treatment of COVID-19, the company said in a statement.

It is a prescription-based drug and will be available as a 200 mg tablet at an MRP of Rs 3,500 for a strip of 34 tablets. The drug will be made available both through hospitals and the retail channel, Glenmark said.

Glenmark is producing the active pharmaceutical ingredients (API) for the drug at its Ankleshwar plant, while the formulation is being manufactured at its Baddi plant.

Favipiravir can be used for coronavirus patients with co-morbid conditions such as diabetes and heart disease with mild to moderate COVID-19 symptoms. It offers a rapid reduction in viral load within 4 days and provides faster symptomatic and radiological improvement. Favipiravir has shown clinical improvement of up to 88 percent in mild to moderate COVID-19 cases, Glenmark said.

Favipiravir is a generic version of Avigan of Japanese company Fujifilm Toyama Chemical, also a subsidiary of Fujifilm Corporation.

If we consider a minimum of two strips per patient, Glenmark will be able to provide FabiFlu for about 82,500 patients in the first month of launch itself.

Read more about: glenmark pharma coronavirus
Company Search
Get Instant News Updates
Enable
x
Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more